I V Moldavskaya

Kuzbass Clinical Cardiology Center named after L.S. Barbarash, Kemerovo, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does I V Moldavskaya research?

I V Moldavskaya studies the use of Revelise (alteplase) in managing ischemic strokes, which occur when blood flow to the brain is blocked, leading to serious health complications. Specifically, they research how effective this treatment is in improving patient outcomes and reducing disabilities following a stroke. Their research involves real-world data from patients, particularly those who are older or have multiple health conditions, making their findings relevant to a wide range of individuals affected by strokes.

Key findings

  • In the International PRIMA Study, 49.9% of the 2,202 patients treated with Revelise had good outcomes at discharge.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%, indicating significant recovery over time.
  • Revelise was shown to effectively reduce stroke-related disabilities, even among older patients and those with other health issues.

Frequently asked questions

Does Dr. Moldavskaya study ischemic strokes?
Yes, Dr. Moldavskaya specifically researches treatments for ischemic strokes using the medication Revelise.
What outcomes does Dr. Moldavskaya's research focus on?
Their research focuses on patient recovery outcomes, including significant improvements in functional independence and reduction of stroke-related disabilities.
Are the results from Dr. Moldavskaya's studies applicable to older stroke patients?
Yes, their findings are particularly relevant for older patients and those with multiple health issues, demonstrating that Revelise can be effective in these groups.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.